{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T13:41:42Z","timestamp":1762177302997,"version":"3.41.2"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2020,6,11]],"date-time":"2020-06-11T00:00:00Z","timestamp":1591833600000},"content-version":"vor","delay-in-days":1,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30-CA015704"],"award-info":[{"award-number":["P30-CA015704"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Seattle Cancer Care Alliance Summer Infection Prevention Intern Support"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>US hematopoietic cell transplantation (HCT) recipients have a low prevalence of latent tuberculosis infection (LTBI), but if latently infected they are at risk for progression to active tuberculosis. At our center, all HCT recipients underwent LTBI testing pretransplant by tuberculin skin testing (TST) until 2013 when we implemented a targeted screening program. Our objective was to assess the utility of our screening program that incorporated a pretransplant LTBI questionnaire to target TST and QuantiFERON TB Gold (QFT) testing.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We performed a retrospective cohort study of HCT recipients undergoing first transplant from 2014 to 2016. Patients with positive, indeterminate, and a subset with negative QFT results underwent electronic medical record (EMR) review to assess TST results and risk factors for LTBI.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Among 1290 eligible recipients, 457 (35%) had at least 1 risk factor for LTBI on the pretransplant questionnaire; nonwhites were more likely to undergo LTBI testing (P\u2005&amp;lt;\u2005.0001). Overall, 16 of 1290 (1.2%) had at least 1 positive LTBI test. Of those screened by QFT, 14 of 457 (3%) were positive and 52 (11%) were indeterminate. Among those undergoing EMR review, 123 of 267 (46%) had TST records; 4 of 123 (3%) positive by both TST and QFT, and 2 (2%) by TST alone. Two or more risk factors were reported among the majority of LTBI-positive patients (15 of 16 [94%]). All patients with at least 1 positive test for LTBI (n\u2005=\u200516) were evaluated, and 11 of 16 (69%) were recommended to receive treatment.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Incorporating a pretransplant LTBI questionnaire allowed for an approximate 65% reduction in LTBI testing when compared with universal testing among this low prevalence population.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ofid\/ofaa224","type":"journal-article","created":{"date-parts":[[2020,6,11]],"date-time":"2020-06-11T00:57:25Z","timestamp":1591837045000},"source":"Crossref","is-referenced-by-count":2,"title":["A Targeted Screening Program for Latent Tuberculosis Infection Among Hematopoietic Cell Transplant Recipients"],"prefix":"10.1093","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4687-426X","authenticated-orcid":false,"given":"Andrea","family":"Sosa-Moreno","sequence":"first","affiliation":[{"name":"School of Public Health, University of Michigan, Ann Arbor, Michigan, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Narita","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Washington, Seattle, Washington, USA"},{"name":"Public Health-Seattle & King County, Seattle, Washington, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9235-840X","authenticated-orcid":false,"given":"Christopher","family":"Spitters","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Washington, Seattle, Washington, USA"},{"name":"Public Health-Seattle & King County, Seattle, Washington, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle","family":"Swetky","sequence":"first","affiliation":[{"name":"Infection Prevention, Seattle Cancer Care Alliance, Seattle, Washington, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Podczervinski","sequence":"first","affiliation":[{"name":"Washington State Department of Health, Shoreline, Washington, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1572-4074","authenticated-orcid":false,"given":"Margaret L","family":"Lind","sequence":"first","affiliation":[{"name":"School of Public Health, University of Washington, Seattle, Washington, USA"},{"name":"Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leona","family":"Holmberg","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Washington, Seattle, Washington, USA"},{"name":"Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7532-4822","authenticated-orcid":false,"given":"Catherine","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Washington, Seattle, Washington, USA"},{"name":"Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA"},{"name":"Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raleigh","family":"Edelstein","sequence":"first","affiliation":[{"name":"Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6333-5196","authenticated-orcid":false,"given":"Steven A","family":"Pergam","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Washington, Seattle, Washington, USA"},{"name":"Infection Prevention, Seattle Cancer Care Alliance, Seattle, Washington, USA"},{"name":"Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA"},{"name":"Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,6,10]]},"reference":[{"key":"2020071002241675300_CIT0001","doi-asserted-by":"crossref","first-page":"a018192","DOI":"10.1101\/cshperspect.a018192","article-title":"Transmission and institutional infection control of tuberculosis","volume":"6","author":"Nardell","year":"2015","journal-title":"Cold Spring Harb Perspect Med"},{"volume-title":"Global tuberculosis report 2019","year":"2019","author":"World Health Organization.","key":"2020071002241675300_CIT0002"},{"key":"2020071002241675300_CIT0003","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1183\/13993003.01245-2015","article-title":"Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries","volume":"46","author":"Getahun","year":"2015","journal-title":"Eur Respir J"},{"key":"2020071002241675300_CIT0004","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1146\/annurev-immunol-032712-095939","article-title":"The immune response in tuberculosis","volume":"31","author":"O\u2019Garra","year":"2013","journal-title":"Annu Rev Immunol"},{"volume-title":"Latent tuberculosis infection: updated and consolidated guidelines for programmatic management","year":"2018","author":"World Health Organization.","key":"2020071002241675300_CIT0005"},{"key":"2020071002241675300_CIT0006","doi-asserted-by":"crossref","first-page":"6","DOI":"10.4046\/trd.2017.0052","article-title":"Treatment of latent tuberculosis infection and its clinical efficacy","volume":"81","author":"Kim","year":"2018","journal-title":"Tuberc Respir Dis (Seoul)"},{"key":"2020071002241675300_CIT0007","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1093\/cid\/ciz048","article-title":"Risk of latent tuberculosis reactivation after hematopoietic cell transplantation","volume":"69","author":"Cheng","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2020071002241675300_CIT0008","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1183\/09031936.00000712","article-title":"The risk of tuberculosis in transplant candidates and recipients: a TBNET consensus statement","volume":"40","author":"Bumbacea","year":"2012","journal-title":"Eur Respir J"},{"key":"2020071002241675300_CIT0009"},{"key":"2020071002241675300_CIT0010","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/sj.bmt.1700686","article-title":"Mycobacterial infections following bone marrow transplantation: a 20 year retrospective review","volume":"19","author":"Roy","year":"1997","journal-title":"Bone Marrow Transplant"},{"key":"2020071002241675300_CIT0011","doi-asserted-by":"crossref","first-page":"e13430","DOI":"10.1111\/ctr.13430","article-title":"An update on Mycobacterium tuberculosis infection after hematopoietic stem cell transplantation in adults","volume":"32","author":"Abad","year":"2018","journal-title":"Clin Transplant"},{"key":"2020071002241675300_CIT0012","doi-asserted-by":"crossref","first-page":"e0173250","DOI":"10.1371\/journal.pone.0173250","article-title":"The demanding attention of tuberculosis in allogeneic hematopoietic stem cell transplantation recipients: high incidence compared with general population","volume":"12","author":"Lee","year":"2017","journal-title":"PLoS One"},{"key":"2020071002241675300_CIT0013","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.bbmt.2009.06.019","article-title":"Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective","volume":"15","author":"Tomblyn","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"author":"Missouri Department of Health and Senior Services Bureau of Communicable Disease Control and Prevention","key":"2020071002241675300_CIT0014"},{"author":"World Health Organization","key":"2020071002241675300_CIT0015"},{"author":"Centers for Disease Control and Prevention","key":"2020071002241675300_CIT0016"},{"key":"2020071002241675300_CIT0017","first-page":"788","article-title":"Booster phenomenon of QuantiFERON-TB Gold after prior intradermal PPD injection","volume":"11","author":"Igari","year":"2007","journal-title":"Int J Tuberc Lung Dis"},{"key":"2020071002241675300_CIT0018","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1183\/09031936.00117506","article-title":"Effect of tuberculin skin testing on a Mycobacterium tuberculosis-specific interferon-gamma assay","volume":"29","author":"Leyten","year":"2007","journal-title":"Eur Respir J"},{"key":"2020071002241675300_CIT0019","doi-asserted-by":"crossref","first-page":"e8517","DOI":"10.1371\/journal.pone.0008517","article-title":"Within-subject variability of interferon-g assay results for tuberculosis and boosting effect of tuberculin skin testing: a systematic review","volume":"4","author":"van Zyl-Smit","year":"2009","journal-title":"PLoS One"},{"key":"2020071002241675300_CIT0020","doi-asserted-by":"crossref","first-page":"e022445","DOI":"10.1136\/bmjopen-2018-022445","article-title":"Screening and prevention for latent tuberculosis in immunosuppressed patients at risk for tuberculosis: a systematic review of clinical practice guidelines","volume":"8","author":"Hasan","year":"2018","journal-title":"BMJ Open"},{"key":"2020071002241675300_CIT0021","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1056\/NEJMcp1005750","article-title":"Clinical practice. Latent tuberculosis infection in the United States","volume":"364","author":"Horsburgh","year":"2011","journal-title":"N Engl J Med"},{"key":"2020071002241675300_CIT0022","doi-asserted-by":"crossref","first-page":"S221","DOI":"10.1164\/ajrccm.161.supplement_3.ats600","article-title":"Targeted tuberculin testing and treatment of latent tuberculosis infection. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. This is a Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). This statement was endorsed by the Council of the Infectious Diseases Society of America. (IDSA), September 1999, and the sections of this statement","volume":"161","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"key":"2020071002241675300_CIT0023","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1128\/JCM.00730-12","article-title":"Investigation of false-positive results given by the QuantiFERON-TB Gold In-Tube assay","volume":"50","author":"Slater","year":"2012","journal-title":"J Clin Microbiol"},{"author":"Panel on Opportunistic Infections in Adults and Adolescents with HIV","key":"2020071002241675300_CIT0024"},{"key":"2020071002241675300_CIT0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.39480","article-title":"2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis","volume":"68","author":"Singh","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2020071002241675300_CIT0026","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1136\/thx.2005.046797","article-title":"BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment","volume":"60","author":"British Thoracic Society Standards of Care Committee","year":"2005","journal-title":"Thorax"},{"key":"2020071002241675300_CIT0027","doi-asserted-by":"crossref","first-page":"36","DOI":"10.4103\/2278-330X.96507","article-title":"Pulmonary tuberculosis as differential diagnosis of lung cancer","volume":"1","author":"Bhatt","year":"2012","journal-title":"South Asian J Cancer"},{"key":"2020071002241675300_CIT0028","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1111\/j.1469-0691.2004.00954.x","article-title":"Mycobacterium tuberculosis at a comprehensive cancer centre: active disease in patients with underlying malignancy during 1990\u20132000","volume":"10","author":"De La Rosa","year":"2004","journal-title":"Clin Microbiol Infect"},{"key":"2020071002241675300_CIT0029","first-page":"77","article-title":"[Lessons learned from tuberculosis outbreak cases]","volume":"89","author":"Kato","year":"2014","journal-title":"Kekkaku"},{"key":"2020071002241675300_CIT0030","doi-asserted-by":"crossref","first-page":"e0187313","DOI":"10.1371\/journal.pone.0187313","article-title":"A borderline range for Quantiferon Gold In-Tube results","volume":"12","author":"Jonsson","year":"2017","journal-title":"PLoS One"},{"key":"2020071002241675300_CIT0031","doi-asserted-by":"crossref","first-page":"e12912","DOI":"10.1111\/tid.12912","article-title":"The incidence of tuberculosis infection in hematopoietic stem cell transplantation recipients: a retrospective cohort study from a center in Turkey","volume":"20","author":"Ak\u0131","year":"2018","journal-title":"Transpl Infect Dis"},{"key":"2020071002241675300_CIT0032","doi-asserted-by":"crossref","first-page":"340","DOI":"10.7326\/0003-4819-146-5-200703060-00006","article-title":"Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research","volume":"146","author":"Menzies","year":"2007","journal-title":"Ann Intern Med"},{"key":"2020071002241675300_CIT0033","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1128\/CMR.00034-13","article-title":"Gamma interferon release assays for detection of Mycobacterium tuberculosis infection","volume":"27","author":"Pai","year":"2014","journal-title":"Clin Microbiol Rev"},{"key":"2020071002241675300_CIT0034","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1183\/09031936.00122109","article-title":"Indeterminate results of a tuberculosis-specific interferon-gamma release assay in immunocompromised patients","volume":"35","author":"Lange","year":"2010","journal-title":"Eur Respir J"},{"key":"2020071002241675300_CIT0035","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ijmyco.2016.02.005","article-title":"The pros and cons of the QuantiFERON test for the diagnosis of tuberculosis, prediction of disease progression, and treatment monitoring","volume":"5","author":"Ndzi","year":"2016","journal-title":"Int J Mycobacteriol"},{"key":"2020071002241675300_CIT0036","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1378\/chest.08-2575","article-title":"Performance of tests for latent tuberculosis in different groups of immunocompromised patients","volume":"136","author":"Richeldi","year":"2009","journal-title":"Chest"},{"key":"2020071002241675300_CIT0037","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.lungcan.2014.07.001","article-title":"Latent TB infection in newly diagnosed lung cancer patients - A multicenter prospective observational study","volume":"85","author":"Fan","year":"2014","journal-title":"Lung Cancer"},{"key":"2020071002241675300_CIT0038","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.3389\/fimmu.2017.01506","article-title":"Low T-cell responses to mitogen stimulation predicts poor survival in recipients of allogeneic hematopoietic stem cell transplantation","volume":"8","author":"Yong","year":"2017","journal-title":"Front Immunol"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofaa224\/33376559\/ofaa224.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ofid\/article-pdf\/7\/7\/ofaa224\/33479952\/ofaa224.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ofid\/article-pdf\/7\/7\/ofaa224\/33479952\/ofaa224.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,10]],"date-time":"2020-07-10T06:24:34Z","timestamp":1594362274000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofaa224\/5855771"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,10]]},"references-count":38,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofaa224","relation":{},"ISSN":["2328-8957"],"issn-type":[{"type":"electronic","value":"2328-8957"}],"subject":[],"published-other":{"date-parts":[[2020,7]]},"published":{"date-parts":[[2020,6,10]]},"article-number":"ofaa224"}}